Literature DB >> 600179

Lactulose in vincristine-induced constipation.

A C Harris, J M Jackson.   

Abstract

Constipation which is resistant to the usual range of laxatives is a troublesome undesirable effect of vincristine. Lactulose in doses up to 25 ml thrice daily proved to be a simple and effective treatment in six patients with refractory vincristine-induced constipation, and a successful prophylactic in two other patients. Palatable, and without any serious undesirable effects, lactulose can improve the quality of life for patients with a malignant tumour which is responsive to vincristine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 600179     DOI: 10.5694/j.1326-5377.1977.tb114646.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.

Authors:  Arjun Datt Law; Gaurav Prakash; Alka Khadwal; Ashim Das; Subhash Varma; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-06       Impact factor: 0.900

Review 2.  [Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].

Authors:  S Bader; M Weber; G Becker
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

3.  Treatment of vincristine-induced ileus with sincalide, a cholecystokinin analog.

Authors:  D V Jackson; W C Wu; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Vincristine-induced abnormalities of gastrointestinal regulatory peptide cells of the rat. An immunocytochemical study.

Authors:  C F Johnston; C Shaw; K D Buchanan
Journal:  Cell Tissue Res       Date:  1985       Impact factor: 5.249

5.  Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat.

Authors:  Gema Vera; Ana E López-Pérez; José A Uranga; Rocío Girón; Ma Isabel Martín-Fontelles; Raquel Abalo
Journal:  Front Pharmacol       Date:  2017-02-06       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.